Curcumin induces apoptotic cell death via Oct4 inhibition and GSK-3β activation in NCCIT cells

Molecular Nutrition and Food Research

Volumn 59, Issue 6, 2015, Pages 1053-1062

  Yun, Ji Ho ^a,b   Park, Young Gyun ^a,c   Lee, Kyung Mi ^a   Kim, Jungho ^b   Nho, Chu Won ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Sogang University   (South Korea)

^c Gangneung Wonju National University   (South Korea)

Author keywords

Apoptotic cell death; Cancer chemoprevention; Curcumin; Oct4; Wnt catenin signaling

Indexed keywords

BETA CATENIN; CURCUMIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER STEM CELL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; RNA, SMALL INTERFERING; WNT SIGNALING PATHWAY;

EID: 84930181383     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400739     Document Type: Article

References (47)

1. Surh, Y. J., Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768-780.
2. Wattenberg, L. W., Chemoprevention of cancer. Cancer Res. 1985, 45, 1-8.
3. Rosner, M. H., Vigano, M. A., Ozato, K., Timmons, P. M. et al., A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature 1990, 345, 686-692.
4. Matoba, R., Niwa, H., Masui, S., Ohtsuka, S. et al., Dissecting Oct3/4-regulated gene networks in embryonic stem cells by expression profiling. PLoS One 2006, 1, e26.
5. Pesce, M., Wang, X., Wolgemuth, D. J., Scholer, H., Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. Mech. Dev. 1998, 71, 89-98.
6. Dai, X., Ge, J., Wang, X., Qian, X. et al., OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol. Rep. 2013, 29, 155-160.
7. Kim, R. J., Nam, J. S., OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab. Anim. Res. 2011, 27, 147-152.
8. Linn, D. E., Yang, X., Sun, F., Xie, Y. et al., A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer 2010, 1, 908-916.
9. Lu, Y., Zhu, H., Shan, H., Lu, J. et al., Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett. 2013, 340, 113-123.
10. Wang, Y. D., Cai, N., Wu, X. L., Cao, H. Z. et al., OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis. 2013, 4, e760.
11. Hu, T., Liu, S., Breiter, D. R., Wang, F. et al., Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008, 68, 6533-6540.
12. Aberle, H., Bauer, A., Stappert, J., Kispert, A., Kemler, R., beta-catenin is a target for the ubiquitin-proteasome pathway. Embo. J. 1997, 16, 3797-3804.
13. Klaus, A., Birchmeier, W., Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8, 387-398.
14. Wodarz, A., Nusse, R., Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 1998, 14, 59-88.
15. Malanchi, I., Peinado, H., Kassen, D., Hussenet, T. et al., Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 452, 650-653.
16. Li, J., Li, J., Chen, B., Oct4 was a novel target of Wnt signaling pathway. Mol. Cell Biochem. 2012, 362, 233-240.
17. Kelly, K. F., Ng, D. Y., Jayakumaran, G., Wood, G. A. et al., beta-catenin enhances Oct-4 activity and reinforces pluripotency through a TCF-independent mechanism. Cell Stem Cell 2011, 8, 214-227.
18. Takebe, N., Harris, P. J., Warren, R. Q., Ivy, S. P., Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8, 97-106.
19. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M. et al., Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21, 2895-2900.
20. Zhou, H., Beevers, C. S., Huang, S., The targets of curcumin. Curr. Drug Targets 2011, 12, 332-347.
21. Norris, L., Karmokar, A., Howells, L., Steward, W. P. et al., The role of cancer stem cells in the anti-carcinogenicity of curcumin. Mol. Nutr. Food Res. 2013, 57, 1630-1637.
22. Lee, J., Kim, H. K., Rho, J. Y., Han, Y. M., Kim, J., The human OCT-4 isoforms differ in their ability to confer self-renewal. J. Biol. Chem. 2006, 281, 33554-33565.
23. Lee, S. B., Kim, C. Y., Lee, H. J., Yun, J. H., Nho, C. W., Induction of the phase II detoxification enzyme NQO1 in hepatocarcinoma cells by lignans from the fruit of Schisandra chinensis through nuclear accumulation of Nrf2. Planta. Med. 2009, 75, 1314-1318.
24. Kang, K., Lee, S. B., Jung, S. H., Cha, K. H. et al., Tectoridin, a poor ligand of estrogen receptor alpha, exerts its estrogenic effects via an ERK-dependent pathway. Mol. Cells 2009, 27, 351-357.
25. Kang, K., Lee, H. J., Kim, C. Y., Lee, S. B. et al., The chemopreventive effects of Saussurea salicifolia through induction of apoptosis and phase II detoxification enzyme. Biol. Pharm. Bull. 2007, 30, 2352-2359.
26. Lee, K. M., Kang, K., Lee, S. B., Nho, C. W., Nuclear factor-E2 (Nrf2) is regulated through the differential activation of ERK1/2 and PKC alpha/betaII by Gymnasterkoreayne B. Cancer Lett. 2013, 330, 225-232.
27. Greber, B., Lehrach, H., Adjaye, J., Silencing of core transcription factors in human EC cells highlights the importance of autocrine FGF signaling for self-renewal. BMC Dev. Biol. 2007, 7, 46.
28. Anto, R. J., Mukhopadhyay, A., Denning, K., Aggarwal, B. B., Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002, 23, 143-150.
29. Yun, J. H., Lee, S. B., Kang, K., Lee, E. H. et al., Bifunctional chemopreventive effects of Adenocaulon himalaicum through induction of detoxification enzymes and apoptosis. J. Med. Food. 2013, 16, 701-710.
30. Guo, Y., Mantel, C., Hromas, R. A., Broxmeyer, H. E., Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin. Stem Cells 2008, 26, 30-34.
31. Wen, K., Fu, Z., Wu, X., Feng, J. et al., Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. Cancer Lett. 2013, 333, 56-65.
32. Beurel, E., Jope, R. S., The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol. 2006, 79, 173-189.
33. Dean, M., Fojo, T., Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284.
34. Zhou, B. B., Zhang, H., Damelin, M., Geles, K. G. et al., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8, 806-823.
35. Samardzija, C., Quinn, M., Findlay, J. K., Ahmed, N., Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J. Ovarian Res. 2012, 5, 37.
36. Li, Z., Li, X., Li, C., Su, Y. et al., Transcription factor OCT4 promotes cell cycle progression by regulating CCND1 expression in esophageal carcinoma. Cancer Lett. 2014, 354, 77-86.
37. Hu, J., Qin, K., Zhang, Y., Gong, J. et al., Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells. Biochem. Biophys. Res. Commun. 2011, 411, 786-791.
38. Shen, L., Qin, K., Wang, D., Zhang, Y. et al., Overexpression of Oct4 suppresses the metastatic potential of breast cancer cells via Rnd1 downregulation. Biochim. Biophys. Acta 2014, 1842, 2087-2095.
39. Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W. et al., Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003, 423, 448-452.
40. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516.
41. Li, H., Zhu, H., Xu, C. J., Yuan, J., Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94, 491-501.
42. Aggarwal, B. B., Kumar, A., Bharti, A. C., Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23, 363-398.
43. Hsu, C. H., Cheng, A. L., Clinical studies with curcumin. Adv. Exp. Med. Biol. 2007, 595, 471-480.
44. Sharma, R. A., McLelland, H. R., Hill, K. A., Ireson, C. R. et al., Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 2001, 7, 1894-1900.
45. Jager, R., Lowery, R. P., Calvanese, A. V., Joy, J. M. et al., Comparative absorption of curcumin formulations. Nutr. J. 2014, 13, 11.
46. Lao, C. D., Ruffin, M. T. t., Normolle, D., Heath, D. D. et al., Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 2006, 6, 10.
47. Yallapu, M. M., Jaggi, M., Chauhan, S. C., Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 2012, 17, 71-80.